TRAILBLAZER-ALZ 2 (NCT04437511) was a landmark Phase 3 clinical trial evaluating donanemab in early symptomatic Alzheimer's disease patients with low-to-medium levels of tau pathology. The trial demonstrated significant clinical slowing of disease progression, leading to FDA approval in 2024[1].
Donanemab represents a significant advancement in Alzheimer's disease therapy as the second anti-amyloid antibody to receive FDA approval, following lecanemab. The trial also pioneered the use of tau-based patient selection, which may improve treatment response prediction.
| Parameter | Value |
|---|---|
| NCT Number | NCT04437511 |
| Phase | Phase 3 |
| Status | Completed |
| Sponsor | Eli Lilly and Company |
| Enrollment | 1,736 patients |
| Duration | 18 months (blinded period) |
| Location | Multiple countries (US, Canada, UK, EU, Japan, Australia) |
| Randomization | 1:1 (donanemab:placebo) |
Donanemab is a monoclonal antibody that targets a specific form of aggregated amyloid-beta plaque with the N3pG (pyroglutamate) epitope[1:1]. This epitope is found on mature, dense-core plaques that are most closely associated with Alzheimer's disease pathology.
Binding Specificity:
The antibody facilitates plaque removal through microglial-mediated clearance:
This mechanism differs from earlier anti-Aβ antibodies that targeted soluble Aβ species, potentially explaining the robust plaque clearance observed with donanemab[2].
Inclusion Criteria:
| Criterion | Requirement |
|---|---|
| Age | 60-85 years |
| Diagnosis | MCI due to AD or mild AD dementia |
| MMSE score | 20-28 |
| Amyloid PET | Positive (centiloid ≥40) |
| Tau PET | Low-to-medium tangles (intermediate tau) |
The trial employed a novel tau-based stratification approach:
This stratification represents a precision medicine approach to AD treatment, matching therapy to disease stage[3].
Screening → Randomization (1:1) → 18-Month Treatment → Follow-up
↓ ↓
Donanemab IV q4w Placebo IV q4w
iADRS (Integrated Alzheimer's Disease Rating Scale) at 18 months:
| Endpoint | Domain |
|---|---|
| CDR-SB | Clinical dementia staging |
| ADAS-Cog13 | Cognitive function |
| ADCS-MCI-ADL | Daily functioning |
| Amyloid PET SUVr | Plaque burden |
| Tau PET | Tau pathology progression |
TRAILBLAZER-ALZ 2 met its primary endpoint with statistically significant results[3:1]:
| Measure | Donanemab | Placebo | Treatment Effect |
|---|---|---|---|
| iADRS change | -6.02 | -10.36 | -4.34 (35% slowing, p<0.001) |
| CDR-SB change | -1.72 | -2.42 | 0.70 (29% slowing) |
Clinical Interpretation:
Plaque Removal:
| Adverse Event | Donanemab | Placebo |
|---|---|---|
| ARIA-E (edema) | 24% | 2% |
| ARIA-H (hemorrhage) | 31% | 13% |
| Infusion reactions | 8% | <1% |
| Discontinuation due to AE | 6% | 2% |
ARIA Management:
In July 2024, the FDA approved donanemab (brand name Kisunly) for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia.
Approval Conditions:
| Feature | Donanemab | Lecanemab | Aducanumab |
|---|---|---|---|
| Target | N3pG-Aβ | Protofibrils | Monomers/oligomers |
| Dosing | q4w IV | q2w IV | q4w IV |
| Plaque clearance | 84-90% | ~60% | ~70% |
| ARIA-E rate | 24% | 13% | 35% |
The 35% slowing of clinical decline represents evidence of disease modification:
TRAILBLAZER-ALZ 3:
Combination Approaches:
Donanemab in Early Alzheimer's Disease. JAMA. 2023. ↩︎ ↩︎
Donanemab in early AD. N Engl J Med. 2021. ↩︎
Donanemab results. JAMA. 2023. ↩︎ ↩︎